KNI 122 | CAS#138228-18-9 | heptapeptide analogue

MedKoo Cat#: 598091 | Name: KNI 122

Description:

WARNING: This product is for research use only, not for human or veterinary use.

KNI 122is a heptapeptide analogue.

Chemical Structure

KNI 122

CAS#138228-18-9

Theoretical Analysis

MedKoo Cat#: 598091

Name: KNI 122

CAS#: 138228-18-9

Chemical Formula: C42H62N9O10

Exact Mass: 852.4620

Molecular Weight: 853.01

Elemental Analysis: C, 59.14; H, 7.33; N, 14.78; O, 18.76

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

KNI 122; KNI-122; KNI122; Ser-Phe-Asn-Pns-Pro-Ile-Val-NH2;

IUPAC/Chemical Name

(2S)-1-(D-seryl-L-phenylalanyl-L-asparaginyl)-1-(3-amino-2-hydroxy-4-phenylbutanoyl)-N-((2S,3S)-1-(((S)-1-amino-3-methyl-1-oxobutan-2-yl)amino)-3-methyl-1-oxopentan-2-yl)-1l4-pyrrolidine-2-carboxamide

InChi Key

KXJXJFDZXACDGY-XXGUTPCCSA-N

InChi Code

InChI=1S/C42H62N9O10/c1-5-24(4)34(40(59)49-33(23(2)3)36(46)55)50-39(58)31-17-12-18-51(31,42(61)35(54)27(43)19-25-13-8-6-9-14-25)41(60)30(21-32(45)53)48-38(57)29(47-37(56)28(44)22-52)20-26-15-10-7-11-16-26/h6-11,13-16,23-24,27-31,33-35,52,54H,5,12,17-22,43-44H2,1-4H3,(H2,45,53)(H2,46,55)(H,47,56)(H,48,57)(H,49,59)(H,50,58)/t24-,27?,28+,29-,30-,31-,33-,34-,35?/m0/s1

SMILES Code

CC(C)[C@@H](C(N)=O)NC([C@H]([C@@H](C)CC)NC([C@H]1[N](C(C(O)C(N)CC2=CC=CC=C2)=O)(C([C@H](CC(N)=O)NC([C@H](CC3=CC=CC=C3)NC([C@@H](CO)N)=O)=O)=O)CCC1)=O)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 853.01 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Strutynska NY, Zatovsky IV, Baumer VN, Ogorodnyk IV, Slobodyanik NS. KNi(0.93)Fe(II)(0.07)Fe(III)(PO4)2: a new type of structure for a compound of composition M(I)M(II)M(III)(PO4)2. Acta Crystallogr C Struct Chem. 2014 Feb;70(Pt 2):160-4. doi: 10.1107/S2053229614000679. Epub 2014 Jan 31. PubMed PMID: 24508960. 2: Kiriyama A, Nishiura T, Yamaji H, Takada K. Physiologically based pharmacokinetics of KNI-272, a tripeptide HIV-1 protease inhibitor. Biopharm Drug Dispos. 1999 May;20(4):199-205. PubMed PMID: 10440795. 3: Goto T, Nakano T, Kohno T, Morimatsu S, Morita C, Hong W, Kiso Y, Nakai M, Sano K. Targets of a protease inhibitor, KNI-272, in HIV-1-infected cells. J Med Virol. 2001 Mar;63(3):203-9. PubMed PMID: 11170058. 4: Kiriyama A, Nishiura T, Yamaji H, Takada K. Metabolic characterization of a tripeptide human immunodeficiency virus type 1 protease inhibitor, KNI-272, in rat liver microsomes. Antimicrob Agents Chemother. 1999 Mar;43(3):549-56. PubMed PMID: 10049266; PubMed Central PMCID: PMC89159. 5: Mueller BU, Anderson BD, Farley MQ, Murphy R, Zuckerman J, Jarosinski P, Godwin K, McCully CL, Mitsuya H, Pizzo PA, Balis FM. Pharmacokinetics of the protease inhibitor KNI-272 in plasma and cerebrospinal fluid in nonhuman primates after intravenous dosing and in human immunodeficiency virus-infected children after intravenous and oral dosing. Antimicrob Agents Chemother. 1998 Jul;42(7):1815-8. PubMed PMID: 9661027; PubMed Central PMCID: PMC105689. 6: Kiriyama A, Nishiura T, Ishino M, Yamamoto Y, Ogita I, Kiso Y, Takada K. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor. Biopharm Drug Dispos. 1996 Dec;17(9):739-51. PubMed PMID: 8968527. 7: Kiriyama A, Sugahara M, Yoshikawa Y, Kiso Y, Takada K. The bioavailability of oral dosage forms of a new HIV-1 protease inhibitor, KNI-272, in beagle dogs. Biopharm Drug Dispos. 1996 Mar;17(2):125-34. PubMed PMID: 8907719. 8: Sugahara M, Kiriyama A, Hamada Y, Kiso Y, Takada K. Absorption of new HIV-1 protease inhibitor, KNI-272, after intraduodenal and intragastric administrations to rats: effect of solvent. Biopharm Drug Dispos. 1995 May;16(4):269-77. PubMed PMID: 7548776. 9: Velazquez-Campoy A, Luque I, Todd MJ, Milutinovich M, Kiso Y, Freire E. Thermodynamic dissection of the binding energetics of KNI-272, a potent HIV-1 protease inhibitor. Protein Sci. 2000 Sep;9(9):1801-9. PubMed PMID: 11045625; PubMed Central PMCID: PMC2144700. 10: Chokekijchai S, Shirasaka T, Weinstein JN, Mitsuya H. In vitro anti-HIV-1 activity of HIV protease inhibitor KNI-272 in resting and activated cells: implications for its combined use with AZT or ddI. Antiviral Res. 1995 Sep;28(1):25-38. PubMed PMID: 8585758. 11: Kiriyama A, Mimoto T, Kiso Y, Takada K. Pharmacokinetic study of a tripeptide HIV-1 protease inhibitor, KNI-174, in rats after intravenous and intraduodenal administrations. Biopharm Drug Dispos. 1993 Apr;14(3):199-207. PubMed PMID: 8490108. 12: Peel AD, Schanda J, Grossmann D, Ruge F, Oberhofer G, Gilles AF, Schinko JB, Klingler M, Bucher G. Tc-knirps plays different roles in the specification of antennal and mandibular parasegment boundaries and is regulated by a pair-rule gene in the beetle Tribolium castaneum. BMC Dev Biol. 2013 Jun 18;13:25. doi: 10.1186/1471-213X-13-25. PubMed PMID: 23777260; PubMed Central PMCID: PMC3698154. 13: Baldwin ET, Bhat TN, Gulnik S, Liu B, Topol IA, Kiso Y, Mimoto T, Mitsuya H, Erickson JW. Structure of HIV-1 protease with KNI-272, a tight-binding transition-state analog containing allophenylnorstatine. Structure. 1995 Jun 15;3(6):581-90. PubMed PMID: 8590019. 14: Wang YX, Freedberg DI, Yamazaki T, Wingfield PT, Stahl SJ, Kaufman JD, Kiso Y, Torchia DA. Solution NMR evidence that the HIV-1 protease catalytic aspartyl groups have different ionization states in the complex formed with the asymmetric drug KNI-272. Biochemistry. 1996 Aug 6;35(31):9945-50. Erratum in: Biochemistry 1997 Jan 7;36(1):280. PubMed PMID: 8756455. 15: Humphrey RW, Wyvill KM, Nguyen BY, Shay LE, Kohler DR, Steinberg SM, Ueno T, Fukasawa T, Shintani M, Hayashi H, Mitsuya H, Yarchoan R. A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infection. Antiviral Res. 1999 Feb;41(1):21-33. PubMed PMID: 10321576. 16: Doi M, Kimura T, Ishida T, Kiso Y. Rigid backbone moiety of KNI-272, a highly selective HIV protease inhibitor: methanol, acetone and dimethylsulfoxide solvated forms of 3-[3-benzyl-2-hydroxy-9-(isoquinolin-5-yloxy)-6-methylsulfanylmethyl-5,8-dioxo-4, 7-diazanonanoyl]-N-tert-butyl-1,3-thiazolidine-4-carboxamide. Acta Crystallogr B. 2004 Aug;60(Pt 4):433-7. Epub 2004 Jul 19. PubMed PMID: 15258401. 17: Kar P, Lipowsky R, Knecht V. Importance of polar solvation and configurational entropy for design of antiretroviral drugs targeting HIV-1 protease. J Phys Chem B. 2013 May 16;117(19):5793-805. doi: 10.1021/jp3085292. Epub 2013 May 8. PubMed PMID: 23614718. 18: Kageyama S, Anderson BD, Hoesterey BL, Hayashi H, Kiso Y, Flora KP, Mitsuya H. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentrations of proteins. Antimicrob Agents Chemother. 1994 May;38(5):1107-11. PubMed PMID: 8067746; PubMed Central PMCID: PMC188158. 19: Adachi M, Ohhara T, Kurihara K, Tamada T, Honjo E, Okazaki N, Arai S, Shoyama Y, Kimura K, Matsumura H, Sugiyama S, Adachi H, Takano K, Mori Y, Hidaka K, Kimura T, Hayashi Y, Kiso Y, Kuroki R. Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4641-6. doi: 10.1073/pnas.0809400106. Epub 2009 Mar 9. PubMed PMID: 19273847; PubMed Central PMCID: PMC2660780. 20: Ohno Y, Kiso Y, Kobayashi Y. Solution conformations of KNI-272, a tripeptide HIV protease inhibitor designed on the basis of substrate transition state: determined by NMR spectroscopy and simulated annealing calculations. Bioorg Med Chem. 1996 Sep;4(9):1565-72. PubMed PMID: 8894113.